📊 ARTL Key Takeaways
Is Artelo Biosciences, Inc.. (ARTL) a Good Investment?
Pre-revenue pharmaceutical company burning $1.2M in operating cash flow quarterly with $3.0M net losses and no visible path to commercialization; while the $10.3M cash position provides 8-9 quarters of runway, the absence of revenue combined with high cash burn in a regulated biotech environment presents significant fundamental risk.
Artelo Biosciences shows extremely weak fundamentals: it remains pre-revenue, generated a $12.88M net loss, and burned $8.52M of cash from operations over the latest period. Financial health is highly stressed, with only $0.60M of cash, a 0.17x current ratio, and negative stockholders' equity, leaving the company dependent on external financing rather than internally funded growth.
Artelo Biosciences, Inc.. Key Strengths (ARTL)
- Strong absolute cash position of $10.3M representing 82% of total assets
- Zero long-term debt with Debt/Equity ratio of 0.00x eliminates solvency risk
- Adequate liquidity with Current Ratio of 1.79x and no forced asset sales needed
- Operating cash burn was lower than net loss, indicating some non-cash expense support to reported earnings
- Capital expenditure needs were minimal, reflecting an asset-light operating model
- No long-term debt burden is disclosed, which limits fixed financing obligations
ARTL Stock Risks: Artelo Biosciences, Inc.. Investment Risks
- Pre-revenue company with no revenue generation in latest period
- Negative quarterly operating cash flow of -$1.2M with limited runway of 8-9 quarters
- Net losses of -$3.0M per period with negative ROE of -44.3% and ROA of -23.6%
- Pharmaceutical sector development and regulatory approval risk with unproven commercialization capability
- No insider trading activity suggests lack of management conviction
- The business has no reported revenue, so growth quality and commercial viability remain unproven
- Liquidity is very weak, with $0.60M cash and a 0.17x current ratio, raising near-term funding risk
- Negative equity and recurring operating losses indicate a fragile balance sheet and ongoing dilution or refinancing risk
Key Metrics to Watch
- Time to regulatory approval and product commercialization
- Quarterly cash burn rate and cash runway depletion
- Operating cash flow trajectory toward breakeven
- Clinical trial progress and pipeline advancement milestones
- Quarterly cash burn relative to cash on hand
- Any sustained revenue generation or material improvement in operating loss
Artelo Biosciences, Inc.. (ARTL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Artelo Biosciences, Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
ARTL Profit Margin, ROE & Profitability Analysis
ARTL vs Healthcare Sector: How Artelo Biosciences, Inc.. Compares
How Artelo Biosciences, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Artelo Biosciences, Inc.. Stock Overvalued? ARTL Valuation Analysis 2026
Based on fundamental analysis, Artelo Biosciences, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Artelo Biosciences, Inc.. Balance Sheet: ARTL Debt, Cash & Liquidity
ARTL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Artelo Biosciences, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-18.30 indicates the company is currently unprofitable.
ARTL Revenue Growth, EPS Growth & YoY Performance
Artelo Biosciences, Inc.. Dividends, Buybacks & Capital Allocation
ARTL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Artelo Biosciences, Inc.. (CIK: 0001621221)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ARTL
What is the AI rating for ARTL?
Artelo Biosciences, Inc.. (ARTL) has a Combined AI Grade of C from Claude (C) and ChatGPT (D) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ARTL's key strengths?
Claude: Strong absolute cash position of $10.3M representing 82% of total assets. Zero long-term debt with Debt/Equity ratio of 0.00x eliminates solvency risk. ChatGPT: Operating cash burn was lower than net loss, indicating some non-cash expense support to reported earnings. Capital expenditure needs were minimal, reflecting an asset-light operating model.
What are the risks of investing in ARTL?
Claude: Pre-revenue company with no revenue generation in latest period. Negative quarterly operating cash flow of -$1.2M with limited runway of 8-9 quarters. ChatGPT: The business has no reported revenue, so growth quality and commercial viability remain unproven. Liquidity is very weak, with $0.60M cash and a 0.17x current ratio, raising near-term funding risk.
What is ARTL's revenue and growth?
Artelo Biosciences, Inc.. reported revenue of N/A.
Does ARTL pay dividends?
Artelo Biosciences, Inc.. does not currently pay dividends.
Where can I find ARTL SEC filings?
Official SEC filings for Artelo Biosciences, Inc.. (CIK: 0001621221) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ARTL's EPS?
Artelo Biosciences, Inc.. has a diluted EPS of $-4.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ARTL's fundamental grade?
Based on our AI fundamental analysis in June 2026, Artelo Biosciences, Inc.. has a C grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ARTL stock overvalued or undervalued?
Valuation metrics for ARTL: ROE of -44.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ARTL's AI grade for 2026?
Our dual AI analysis gives Artelo Biosciences, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ARTL's free cash flow?
Artelo Biosciences, Inc..'s operating cash flow is $-1.2M, with capital expenditures of $0.0.
How does ARTL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -44.3% (avg: 15%), current ratio 1.79 (avg: 2).